News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
745,882 Results
Type
Article (44792)
Company Profile (280)
Press Release (700794)
Multimedia
Podcasts (93)
Webinars (24)
Section
Business (210077)
Career Advice (2177)
Deals (36193)
Drug Delivery (127)
Drug Development (82740)
Employer Resources (179)
FDA (16718)
Job Trends (15317)
News (354579)
Policy (33522)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2742)
Accelerated approval (42)
Adcomms (31)
Allergies (160)
Alliances (50902)
ALS (193)
Alzheimer's disease (1770)
Antibody-drug conjugate (ADC) (374)
Approvals (17031)
Artificial intelligence (615)
Autoimmune disease (227)
Automation (52)
Bankruptcy (367)
Best Places to Work (11822)
BIOSECURE Act (20)
Biosimilars (205)
Biotechnology (178)
Bladder cancer (177)
Brain cancer (65)
Breast cancer (696)
Cancer (5368)
Cardiovascular disease (446)
Career advice (1850)
Career pathing (42)
CAR-T (303)
CDC (56)
Celiac Disease (2)
Cell therapy (815)
Cervical cancer (41)
Clinical research (71152)
Collaboration (1934)
Company closure (4)
Compensation (1270)
Complete response letters (69)
COVID-19 (2788)
CRISPR (101)
C-suite (997)
Cystic fibrosis (148)
Data (7103)
Decentralized trials (3)
Denatured (31)
Depression (153)
Dermatology (58)
Diabetes (557)
Diagnostics (7056)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (46)
Drug discovery (307)
Drug pricing (200)
Drug shortages (29)
Duchenne muscular dystrophy (266)
Earnings (93032)
Editorial (61)
Employer branding (22)
Employer resources (157)
Events (121599)
Executive appointments (1053)
FDA (20160)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1638)
Gene editing (213)
Generative AI (54)
Gene therapy (667)
GLP-1 (1039)
Government (4819)
Grass and pollen (6)
Guidances (397)
Healthcare (19330)
HIV (77)
Huntington's disease (53)
IgA nephropathy (91)
Immunology and inflammation (273)
Immuno-oncology (82)
Indications (157)
Infectious disease (3106)
Inflammatory bowel disease (206)
Inflation Reduction Act (14)
Influenza (131)
Intellectual property (276)
Interviews (335)
IPO (16882)
IRA (50)
Job creations (3815)
Job search strategy (1550)
JPM (58)
Kidney cancer (18)
Labor market (93)
Layoffs (567)
Leadership (40)
Legal (8128)
Liver cancer (99)
Longevity (29)
Lung cancer (725)
Lymphoma (406)
Machine learning (53)
Management (61)
Manufacturing (933)
MASH (177)
Medical device (14171)
Medtech (14250)
Mergers & acquisitions (20480)
Metabolic disorders (1430)
mRNA (178)
Multiple sclerosis (173)
NASH (17)
Neurodegenerative disease (390)
Neuropsychiatric disorders (97)
Neuroscience (3179)
Neurotech (1)
NextGen: Class of 2026 (6690)
Non-profit (4669)
Now hiring (73)
Obesity (678)
Opinion (292)
Ovarian cancer (185)
Pain (229)
Pancreatic cancer (258)
Parkinson's disease (348)
Partnered (34)
Patents (556)
Patient recruitment (592)
Peanut (60)
People (60861)
Pharmaceutical (62)
Pharmacy benefit managers (32)
Phase 1 (22169)
Phase 2 (31308)
Phase 3 (23317)
Pipeline (7143)
Policy (307)
Postmarket research (2656)
Preclinical (9482)
Press Release (68)
Prostate cancer (278)
Psychedelics (51)
Radiopharmaceuticals (305)
Rare diseases (1002)
Real estate (6231)
Recruiting (72)
Regulatory (25517)
Reports (54)
Research institute (2538)
Resumes & cover letters (366)
Rett syndrome (32)
RNA editing (17)
RSV (85)
Schizophrenia (166)
Series A (272)
Series B (201)
Service/supplier (13)
Sickle cell disease (107)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3734)
State (2)
Stomach cancer (18)
Supply chain (119)
Tariffs (87)
The Weekly (60)
Vaccines (1077)
Venture capital (100)
Weight loss (431)
Women's health (112)
Worklife (21)
Date
Last 7 days (645)
Last 30 days (2495)
Last 365 days (30309)
2026 (8093)
2025 (30602)
2024 (35662)
2023 (40638)
2022 (51882)
2021 (56491)
2020 (55040)
2019 (47733)
2018 (35924)
2017 (33127)
2016 (32640)
2015 (38702)
2014 (32387)
2013 (27431)
2012 (29685)
2011 (30306)
2010 (28324)
Location
Africa (804)
Alabama (90)
Alaska (7)
Arizona (337)
Arkansas (13)
Asia (41381)
Australia (6800)
California (12345)
Canada (3528)
China (1258)
Colorado (525)
Connecticut (526)
Delaware (368)
Europe (90486)
Florida (1853)
Georgia (401)
Hawaii (3)
Idaho (63)
Illinois (964)
India (83)
Indiana (565)
Iowa (23)
Japan (494)
Kansas (130)
Kentucky (44)
Louisiana (39)
Maine (85)
Maryland (1495)
Massachusetts (8862)
Michigan (355)
Minnesota (682)
Mississippi (6)
Missouri (147)
Montana (33)
Nebraska (29)
Nevada (137)
New Hampshire (84)
New Jersey (3293)
New Mexico (29)
New York (3261)
North Carolina (1597)
North Dakota (9)
Northern California (6082)
Ohio (380)
Oklahoma (23)
Oregon (41)
Pennsylvania (2487)
Puerto Rico (26)
Rhode Island (50)
South America (1177)
South Carolina (76)
South Dakota (1)
Southern California (4865)
Tennessee (199)
Texas (1947)
United States (43857)
Utah (373)
Vermont (1)
Virginia (295)
Washington D.C. (82)
Washington State (988)
West Virginia (4)
Wisconsin (127)
Wyoming (2)
745,882 Results for "merus labs international inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Genmab Buys Rising Cancer Star Merus for $8B
The centerpiece of the acquisition is petosemtamab, Merus’ bispecific antibody targeting EGFR and LGR5, which in May demonstrated best-in-class potential for head-and-neck cancer.
September 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
March 18, 2026
·
7 min read
Press Releases
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
March 9, 2026
·
9 min read
Press Releases
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 15, 2025
·
7 min read
Cancer
Bicara Responds to Rival Merus With Early Survival Data at ASCO25
Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted positive results for its monocolonal antibody, but analysts say Merus still has the upper hand.
June 2, 2025
·
2 min read
·
David Adam
Press Releases
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
·
6 min read
Cancer
Merus’ Bispecific Shows ‘Best in Disease’ Profile in Head-and-Neck Cancer Ahead of ASCO
Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the first-line setting for this indication.
May 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
December 12, 2025
·
6 min read
Press Releases
Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
February 17, 2026
·
2 min read
Antibody-drug conjugates
Merus and Biohaven Strike New ADC Collaboration
On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.
January 13, 2025
·
1 min read
·
Dan Samorodnitsky
1 of 74,589
Next
